Home・Lista de Ações・Coherus Oncology Inc

Coherus Oncology Inc

Fechado

SetorSaúde

1.15 -4.17

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.15

Máximo

1.23

Indicadores-chave
By Trading Economics
Rendimento	-21M -59M
Vendas	2M 14M
P/E Médio do Setor	3.509 57.002
EPS	-0.22
Margem de lucro	-412.092
Funcionários	144
EBITDA	2.8M -31M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+540.5% upside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-31M 192M
Abertura anterior	5.32
Fecho anterior	1.15

Sentimento de Notícias

By Acuity

50%

152 / 340 Ranking em Healthcare

Coherus Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de ago. de 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 de ago. de 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 de ago. de 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 de ago. de 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

7 de ago. de 2026, 23:21 UTC

Coherus BioSciences Inc shares are rising in after-market trading, following a Labor Department report that reduced expectations for a Federal Reserve rate hike.

6 de ago. de 2026, 23:21 UTC

Coherus BioSciences Inc shares fell in after-market trading, reflecting ongoing weakness and volatility amid a lack of specific news to explain the decline.

5 de ago. de 2026, 23:01 UTC

News

Coherus BioSciences shares are lower in after-market trading following a second-quarter adjusted EPS of -$0.19, despite exceeding estimates. Sales missed expectations at $14.31 million.

4 de ago. de 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

3 de ago. de 2026, 19:44 UTC

Coherus BioSciences Inc shares are higher during Monday's session, continuing a notable advance since Friday's close, despite trading below its 20-day moving average.

31 de jul. de 2026, 20:06 UTC

Coherus BioSciences shares are lower today, amid rising U.S. Treasury yields and crude oil prices, which have heightened inflation concerns and interest rate expectations.

30 de jul. de 2026, 22:46 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting a positive response amid broader market recovery despite no specific company news identified.

29 de jul. de 2026, 18:46 UTC

Macro Event

Coherus BioSciences Inc shares are lower today amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 de jul. de 2026, 17:31 UTC

Coherus BioSciences Inc shares are higher during Monday's session, reflecting broader market trends amid declining oil prices that have eased inflation concerns.

23 de jul. de 2026, 19:56 UTC

Coherus BioSciences Inc is trading lower amid broader market concerns over corporate earnings and inflation pressures. Shares remain below their 20-day moving average.

22 de jul. de 2026, 18:26 UTC

Coherus BioSciences Inc shares are trading lower amid broader market pressures, remaining near the lower end of their one-month range. No specific news was identified.

21 de jul. de 2026, 19:41 UTC

Social Media

Coherus BioSciences Inc shares are higher as analysts set a $7 average price target, with potential for positive data readouts this month.

20 de jul. de 2026, 17:31 UTC

Coherus BioSciences Inc. shares are roughly flat today, showing little change since Friday's close amid routine trading activity within a one-month range.

Comparação entre Pares

Variação de preço

Coherus Oncology Inc Previsão

Preço-alvo

By TipRanks

540.5% parte superior

Previsão para 12 meses

Média 7.75 USD 540.5%

Máximo 10 USD

Mínimo 4 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Coherus Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Coherus Oncology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

152 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.